Bristol-Myers Squibb enters a collaboration agreement with Reckitt Benckiser Group plc
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced it has entered into a three-year collaboration agreement with Reckitt Benckiser Group plc (LSE: RBL) for several of its over-the-counter medicines currently sold across Latin America, primarily in Mexico and Brazil.
Sanofi delivers solid 2012 results despite patent expirations
- Details
- Category: Sanofi
In the fourth quarter of 2012, Sanofi (EURONEXT: SAN and NYSE: SNY) generated sales of €8,526 million, an increase of 0.2% on a reported basis. Exchange rate movements had a positive effect of 1.9 percentage points primarily reflecting the appreciation of the U.S. dollar and, to a lesser extent, the appreciation of the Chinese Yuan, Mexican Peso, Australian dollar and British Pound against the Euro.
Novo Nordisk increased operating profit by 32% in 2012
- Details
- Category: Novo Nordisk
Novo Nordisk has announced that sales increased by 18% to 78.0 billion in Danish kroner and by 12% in local currencies. Reported operating profit increased by 32% to DKK 29.5 billion including a 1.7 percentage points improvement in the gross margin. Measured in local currencies, operating profit increased by 20%.
Roche delivers strong 2012 results
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) delivered a strong performance in 2012, with Group sales rising 4% to 45.5 billion Swiss francs due to growing demand for its cancer medicines and increased sales of diagnostic tests to clinical laboratories. This solid sales growth, along with productivity improvements, resulted in a double-digit increase in core operating profit and core earnings per share (EPS), as well as improved profitability.
AstraZeneca fourth quarter and full year results 2012
- Details
- Category: AstraZeneca
AstraZeneca's revenue in the fourth quarter was down 15 percent at constant exchange rates (CER) and declined by 16 percent on an actual basis as a result of the negative impact of exchange rate movements. Loss of exclusivity on several key brands accounted for the revenue decline.
GSK response to news article in The Guardian on UK legal proceedings related to Avandia
- Details
- Category: GlaxoSmithKline
Responding to a news article in The Guardian on UK legal proceedings related to our type 2 diabetes medicine Avandia (rosiglitazone), we would like to make the following points: We have every sympathy for people with health complications associated with diabetes and those who care for them. However, respecting the UK court process, we are unable to comment on ongoing legal cases.
Bristol-Myers Squibb reports fourth quarter financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has announced results for the fourth quarter of 2012 highlighted by regulatory approvals for Eliquis® and Forxiga®. This concluded a year in which the Company delivered growth of its key products as it transitioned to its promising future portfolio. In addition, the company provided financial guidance for 2013.
More Pharma News ...
- Amgen's full year 2012 revenues increased 11 percent to $17.3 billion
- Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013
- Takeda establishes new trading company and reinforces business structure in China
- Novartis makes progress in the fight to eliminate leprosy worldwide
- FDA grants priority review to Boehringer Ingelheim's Afatinib* NDA for EGFR mutation-positive advanced NSCLC
- Sanofi updates its Research & Development pipeline
- Phase III data show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC